Aclaris Therapeutics, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period
Aclaris is a clinical-stage biopharmaceutical company developing therapies for immuno-inflammatory diseases through its KINect platform and preclinical capabilities. It also provides contract research services and is pursuing strategic alternatives and development or commercialization partnerships. This unaudited report covers the three months ended March 31, 2024, compared with the same period in 2023.
Key programs include ATI-2138, lepzacitinib, zunsemetinib and discovery-stage candidates. In January 2024, the company announced a strategic review of its business.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $2.4 million | $2.5 million | Down $0.1 million |
| Contract research revenue | $0.7 million | $0.9 million | Down $0.2 million |
| Licensing revenue | $1.7 million | $1.6 million | Up $0.1 million |
| Research and development | $9.8 million | $22.6 million | Down $12.7 million |
| General and administrative | $6.8 million | $8.8 million | Down $1.9 million |
| Operating loss | $18.9 million | $29.9 million | Improved $11.0 million |
| Net loss | $16.9 million | $28.2 million | Improved $11.2 million |
| Net loss per share | $0.24 | $0.42 | Improved |
| Cash used in operations | $20.8 million | $26.4 million | Improved $5.5 million |
The calculated operating margin was approximately negative 789% and the net margin approximately negative 707%, reflecting the company’s very low revenue base relative to operating expenses. The filing does not present a gross profit or gross margin because management does not consider gross profit meaningful at the current revenue level.
Cash, cash equivalents and marketable securities totaled $161.4 million at March 31, 2024, consisting of $35.8 million of cash and cash equivalents and $125.5 million of marketable securities. Total assets were $174.1 million and stockholders’ equity was $142.0 million. The company had no reported debt facilities or other ongoing material financing commitments, apart from contingent consideration and lease obligations.
The company’s accumulated deficit was $787.7 million. Management believes existing liquidity will fund operating and capital expenditure requirements for more than 12 months from the issuance date of the financial statements, but states that additional capital will be required to develop drug candidates and support discovery efforts.
Material changes versus the prior comparable period
- R&D expense declined 56%, primarily because clinical development activities for zunsemetinib, lepzacitinib and ATI-2138 were reduced or completed.
- General and administrative expense declined 22%, primarily due to lower stock-based compensation and professional fees, partly offset by restructuring-related termination benefits.
- Revenue declined modestly as lower contract research revenue more than offset higher licensing revenue. Licensing revenue primarily reflected higher royalties under the Lilly agreement, while the prior-year period included a commercial milestone.
- Operating and net losses improved substantially, although the company remained loss-making and cash-flow negative.
- The company recorded a $2.8 million expense from revaluation of contingent consideration, compared with an $0.8 million benefit in Q1 2023. The liability increased to $9.0 million from $6.2 million at December 31, 2023, primarily due to changes in estimated sales levels and probabilities of success.
- Operating cash use decreased to $20.8 million from $26.4 million, but cash and cash equivalents fell by $4.0 million during the quarter to $35.8 million.
- A workforce reduction of approximately 46%, approved in December 2023, remained in progress and was expected to be substantially completed by June 2024. The company recognized $2.5 million of severance expense and paid $3.0 million of severance during the quarter.
Guidance, outlook, risks and unusual items
The company expects continued net losses and significant expenses as it advances drug candidates and discovery programs. No specific revenue, earnings or cash-burn guidance was provided.
- ATI-2138 is planned to advance into a Phase 2a trial in moderate-to-severe atopic dermatitis following positive Phase 1 results.
- Lepzacitinib reported positive top-line Phase 2b results in atopic dermatitis; the company is seeking a global development and commercialization partner outside Greater China.
- Zunsemetinib development in immuno-inflammatory diseases was discontinued in 2023. The company plans to support investigator-initiated Phase 1b/2 oncology trials, primarily funded by grants to Washington University.
- The December 2023 Sun Pharma license generated a $15.0 million upfront payment at execution and may generate future milestones and royalties, but the filing does not report additional Q1 2024 upfront proceeds from that agreement.
- The company remains dependent on successful clinical development, regulatory approvals, licensing or partnering transactions, and additional financing. Failure to obtain funding or partners could require significant curtailment of operations.
- Remaining contingent consideration under the Confluence acquisition may reach up to $75.0 million, plus potential royalties and payments tied to future licensing or transfers of acquired intellectual property.
- Aggregate remaining lease payment obligations were $4.5 million at March 31, 2024. The company fully reserved amounts due from EPI Health following its bankruptcy proceedings.
- Management concluded that no substantial doubt existed about the company’s ability to continue as a going concern within one year after issuance of the financial statements, while also acknowledging the need for additional capital over the longer term.
Most important facts for investors to verify
- Timing, design, funding requirements and regulatory progress for the planned ATI-2138 Phase 2a trial.
- Progress toward a global partner for lepzacitinib and any resulting upfront, milestone or royalty economics.
- Actual completion costs and cash savings from the workforce reduction.
- Quarterly cash burn, investment maturities and the estimated duration of the $161.4 million liquidity balance.
- Probability assumptions, sales estimates and potential payment timing underlying the $9.0 million Level 3 contingent consideration liability.
- Whether future licensing, partnership or financing transactions are completed on terms sufficient to support continued development.
- Clinical, regulatory and commercial risks for the remaining pipeline, including the possibility of trial delays, unfavorable results or discontinuation.